

REMARKS

Upon entry of the present amendment, claims 7-16, 24, and 26-39 will be pending.

Applicants have amended claims 7, 8, 10, 13, 24, and 30; cancelled claims 1-6 and 25; and added new claims 35-39. Support for these amendments and new claims can be found throughout the application as filed, e.g., at page 7, line 32, to page 8, line 9; page 18, lines 22-29; and the claims as filed, e.g., claim 5, *inter alia*. No new matter has been added.

Restriction Requirement

Responsive to the action mailed August 24, 2007, applicants elect the invention of Group II, drawn to nucleic acids encoding a recombinant chimeric envelope protein.


Applicants submit that claims 7-12 and 35-39 all relate to nucleic acids and retroviral particles comprising said nucleic acids (i.e., group II), and amended claims 13-16, 24 and 25-34 relate to methods of making or using said nucleic acids. Applicants therefore request rejoinder of the method claims upon a finding of allowability of the claims of group II (see, e.g., MPEP § 821.04(b)).

Applicants further select RGD ligands as the species of heterologous short peptide ligands, and submit that claims 7-16, 24, and 26-39 are readable thereon.

Please apply any charges or credits to deposit account 06-1050, referencing Attorney Docket No. 07917-166US1.

Respectfully submitted,

Date: Sept. 24, 2007


Janice Kugler DeYoung
Reg. No. 50,429

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906
21742427.doc